Asterand extends deal with Bristol-Myers Squibb

The agreement will focus on access to Asterand's PhaseZERO drug discovery services and its XpressBANKTM of human tissue and clinical samples for the continued validation of early drug targets and support for compound optimisation.

Asterand chief executive Martyn Coombs said: "This decision by Bristol-Myers Squibb is an important validation of Asterand's products and services.

"Asterand provides human based solutions that improve decision making during the development of medicines.

"Our customers incorporate human tissue-based models at all stages of development from target identification to pre-clinical research.

"We are delighted that Bristol-Myers Squibb has renewed our collaboration and our team looks forward to continuing to support their target validation and compound optimisation programmes."

Story provided by Business Financial Newswire